Regulus Therapeutics is a San Diego-based biopharmaceutical company dedicated to transforming the lives of patients and their families by delivering groundbreaking therapeutics for orphan kidney diseases. With a focus on high unmet needs, their pipeline programs, including ADPKD, target the underlying biology of these diseases using a novel and potentially powerful approach known as MicroRNA-based therapeutics.
Driven by their mission, Regulus Therapeutics is committed to improving the lives of patients suffering from kidney diseases through their clinical trials and innovative research. Their recent completion of enrollment in the third cohort of a Phase 1b Multiple-Ascending Dose (MAD) clinical trial for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) showcases their dedication to advancing therapeutic solutions in this field.
Generated from the website